Investors Can Lead Securities Fraud Lawsuit Against Capricor Therapeutics
Schall, Brown & Schwartz LLP reminds investors of a class action lawsuit against Capricor Therapeutics. The suit alleges violations of securities laws.
National shareholder rights law firm Schall, Brown & Schwartz LLP (SBS) has notified investors of a class action lawsuit filed against Capricor Therapeutics, Inc. The lawsuit, filed in the U.S. District Court for the Central District of California, alleges violations of federal securities laws, specifically §§10(b) and 20(a).
The suit claims that Capricor Therapeutics made misleading or false statements to investors. While the specific details of these allegations are not provided in the release, they typically pertain to a company's business operations, financial condition, or prospects.
SBS Law is seeking investors who purchased CAPR stock to potentially serve as lead plaintiff in the litigation. Individuals interested in this role are encouraged to contact the firm for more information regarding their rights and the legal process.
This legal action could potentially impact Capricor Therapeutics' stock performance and investor confidence. The company is expected to respond to the allegations as the case proceeds through the court system. Further details are available on the SBS Law website.